OncRef

Clinical Trial: NCT05379803

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Status:

UNKNOWN

Phase:

Phase 2

Lead Sponsor:Hunan Province Tumor Hospital
Information Provided By:Hunan Province Tumor Hospital
Last Update Posted:2024-09-19

Study Overview

Brief Summary

EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC. Whether EGFR mutated NSCLC with CNS metastases can benefit from first-line treatment of high-dose furmonertinib has not been reported. This study aims to investigate the efficacy and safety of high dose furmonertinib in first-line treatment of EGFR mutated NSCLC patiens.

Official Title

A Single Arm, Multicenter Clinical Study of High-dose Furmonertinib in First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Furmonertinib

Other Study ID Numbers

  • FORCE

Start Date (Actual)

2022-05-01

Primary Completion Date (Estimated)

2024-12-31

Study Completion Date (Estimated)

2025-03-31

Enrollment (Estimated)

40

Study Type

Interventional

Phase

Phase 2